<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658134</url>
  </required_header>
  <id_info>
    <org_study_id>SGH-ENDO-Glycine002</org_study_id>
    <nct_id>NCT04658134</nct_id>
  </id_info>
  <brief_title>Glycine &quot;Deficiency&quot; and the Kinetics of Acylglycine in Morbid Obesity</brief_title>
  <official_title>Glycine &quot;Deficiency&quot; and the Kinetics of Acylglycine in Morbid Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Health System, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effects of oral glycine supplementation on plasma glycine&#xD;
      concentration, intracellular glutathione (GSH) concentration, plasma acylglycine&#xD;
      concentration, urine acylglycine concentration, and insulin resistance in subjects with&#xD;
      morbid obesity.&#xD;
&#xD;
      This is an open-labelled trial. 20 adults with morbid obesity will be recruited. Following&#xD;
      screening and baseline metabolic evaluations, eligible subjects will be given oral glycine&#xD;
      supplements for 14 ± 5 days. Upon completing glycine supplementation, subjects will return&#xD;
      for their post-supplement metabolic assessment.&#xD;
&#xD;
      The investigators hypothesize that oral glycine supplementation in morbidly obese patients&#xD;
      normalizes plasma glycine concentration, increases intracellular GSH concentration, increases&#xD;
      plasma and urinary acylglycine concentration, and improves insulin resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amino acid concentration</measure>
    <time_frame>14 days</time_frame>
    <description>Post-treatment changes amino acid concentration in plasma and red blood cell</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acylglycine concentration</measure>
    <time_frame>14 days</time_frame>
    <description>Post-treatment changes acylglycine concentration in plasma and urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acylcarnitine concentration</measure>
    <time_frame>14 days</time_frame>
    <description>Post-treatment changes acylcarnitine concentration in plasma and urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glutathione concentration</measure>
    <time_frame>14 days</time_frame>
    <description>Post-treatment changes in glutathione concentration in plasma and red blood cell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance index</measure>
    <time_frame>14 days</time_frame>
    <description>Post-treatment changes in insulin resistance index</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Glycine; Metabolic Disorder</condition>
  <arm_group>
    <arm_group_label>Glycine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycine supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glycine</intervention_name>
    <description>Oral glycine tablets (100 mg/kg/day) in divided doses</description>
    <arm_group_label>Glycine supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 21-65 years&#xD;
&#xD;
          2. BMI ≥ 32.5 kg/m2&#xD;
&#xD;
          3. Able to provide informed consent&#xD;
&#xD;
          4. Able to maintain present diet throughout the study duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Weight &gt; 150 kg&#xD;
&#xD;
          2. Type 2 Diabetes Mellitus&#xD;
&#xD;
          3. Allergy to soy&#xD;
&#xD;
          4. Ongoing treatment with weight-loss medications (e.g. orlistat, phentermine,&#xD;
             liraglutide)&#xD;
&#xD;
          5. Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)&#xD;
&#xD;
          6. Renal impairment (estimated creatinine clearance estimated by Cockcroft-Gault Equation&#xD;
             &lt; 60 ml/min)&#xD;
&#xD;
          7. Haemoglobin concentration &lt; 10 g/L&#xD;
&#xD;
          8. Serum alanine aminotransferase or aspartate aminotransferase above 2x upper limit of&#xD;
             normal&#xD;
&#xD;
          9. Uncontrolled hypertension (BP &gt; 180/110 mmHg)&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. Nursing mothers&#xD;
&#xD;
         12. Uncontrolled thyroid disease&#xD;
&#xD;
         13. Surgery requiring general anaesthesia within 4-weeks before enrolment&#xD;
&#xD;
         14. Psychiatric disorders requiring medication&#xD;
&#xD;
         15. Significant alcohol intake (&gt; 1 unit per day for women and &gt; 2 units per day for men)&#xD;
&#xD;
         16. Cancer within the last 3-years (except squamous cell and basal cell cancer of the&#xD;
             skin)&#xD;
&#xD;
         17. Any factors likely to limit adherence to study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Chang Tan, MBBS, MMed</last_name>
      <phone>+65-63214658</phone>
      <email>tan.hong.chang@sgh.com.sg</email>
    </contact>
    <contact_backup>
      <last_name>Vieon Wu</last_name>
      <phone>+65-63214658</phone>
      <email>vieon.wu.aini@sgh.com.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Hong Chang Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Morbid obesity</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Glycine metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

